| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A chemistry wiki to facilitate and enhance compound design in drug discovery
|
Robb, Graeme R.
|
|
2013
|
|
3-4 |
p. 141-147
7 p.
|
artikel
|
| 2 |
Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant
|
Maynadier, Marie
|
|
2009
|
|
3-4 |
p. 192-197
6 p.
|
artikel
|
| 3 |
A guidance for renal biomarker lead optimization and use in translational pharmacodynamics
|
Ozer, Josef S.
|
|
2010
|
|
3-4 |
p. 142-147
6 p.
|
artikel
|
| 4 |
Being a Scientist today: are you still having fun?
|
Anastasia, Luigi
|
|
2013
|
|
3-4 |
p. 107-109
3 p.
|
artikel
|
| 5 |
Biologics: a new approach needed?
|
Foster, Keith A.
|
|
2010
|
|
3-4 |
p. 81-83
3 p.
|
artikel
|
| 6 |
Biomarkers of Parkinson's disease: current status and future perspectives
|
Wang, Jian
|
|
2013
|
|
3-4 |
p. 155-162
8 p.
|
artikel
|
| 7 |
Biomimetic tissues on a chip for drug discovery
|
Ghaemmaghami, Amir M.
|
|
2012
|
|
3-4 |
p. 173-181
9 p.
|
artikel
|
| 8 |
Biotechnology in Ireland: hard work, money and the brain gain
|
O’Neill, Michael F
|
|
2007
|
|
3-4 |
p. 108-111
4 p.
|
artikel
|
| 9 |
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
|
Carden, Craig P.
|
|
2010
|
|
3-4 |
p. 88-97
10 p.
|
artikel
|
| 10 |
Chemical probes for biological systems
|
Garcia-Serna, Ricard
|
|
2011
|
|
3-4 |
p. 99-106
8 p.
|
artikel
|
| 11 |
Chromatin-modulating agents as epigenetic anticancer drugs – ‘the die is cast’
|
Konstantinopoulos, Panagiotis A.
|
|
2006
|
|
3-4 |
p. 91-93
3 p.
|
artikel
|
| 12 |
Circulating tumour-derived predictive biomarkers in oncology
|
Hodgson, Darren R.
|
|
2010
|
|
3-4 |
p. 98-101
4 p.
|
artikel
|
| 13 |
Combinatorial chemistry improves molecular options over pre-existing leads
|
Edwards, Paul
|
|
2007
|
|
3-4 |
p. 185-186
2 p.
|
artikel
|
| 14 |
Contents
|
|
|
2013
|
|
3-4 |
p. i-
1 p.
|
artikel
|
| 15 |
Contents
|
|
|
2013
|
|
3-4 |
p. iii-
1 p.
|
artikel
|
| 16 |
Contents
|
|
|
2012
|
|
3-4 |
p. i-
1 p.
|
artikel
|
| 17 |
Contents
|
|
|
2012
|
|
3-4 |
p. iii-
1 p.
|
artikel
|
| 18 |
Contents page 2
|
|
|
2009
|
|
3-4 |
p. iii-
1 p.
|
artikel
|
| 19 |
Contents page 1
|
|
|
2009
|
|
3-4 |
p. i-
1 p.
|
artikel
|
| 20 |
Contents page 2
|
|
|
2010
|
|
3-4 |
p. iii-
1 p.
|
artikel
|
| 21 |
Contents page 1
|
|
|
2010
|
|
3-4 |
p. i-
1 p.
|
artikel
|
| 22 |
Contents page 1
|
|
|
2008
|
|
3-4 |
p. i-
1 p.
|
artikel
|
| 23 |
Contents page 1
|
|
|
2011
|
|
3-4 |
p. i-
1 p.
|
artikel
|
| 24 |
Contents page 2
|
|
|
2011
|
|
3-4 |
p. iii-
1 p.
|
artikel
|
| 25 |
Current and future ophthalmic drug delivery systems
|
del Amo, Eva M.
|
|
2008
|
|
3-4 |
p. 135-143
9 p.
|
artikel
|
| 26 |
Diary
|
|
|
2007
|
|
3-4 |
p. 187-
1 p.
|
artikel
|
| 27 |
Disease induction by human microbial pathogens in plant-model systems: potential, problems and prospects
|
van Baarlen, Peter
|
|
2007
|
|
3-4 |
p. 167-173
7 p.
|
artikel
|
| 28 |
Drosophila models pioneer a new approach to drug discovery for Parkinson's disease
|
Whitworth, Alexander J.
|
|
2006
|
|
3-4 |
p. 119-126
8 p.
|
artikel
|
| 29 |
Editorial Board
|
|
|
2008
|
|
3-4 |
p. iii-
1 p.
|
artikel
|
| 30 |
Effective pharmaceutical regulation needs alignment with doctors
|
Ebbers, Hans C.
|
|
2012
|
|
3-4 |
p. 100-103
4 p.
|
artikel
|
| 31 |
Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials
|
Mimeault, Murielle
|
|
2013
|
|
3-4 |
p. 128-140
13 p.
|
artikel
|
| 32 |
Emerging chemical and biological approaches for the preparation of discovery libraries
|
Boldt, Grant E.
|
|
2006
|
|
3-4 |
p. 143-148
6 p.
|
artikel
|
| 33 |
Erratum
|
|
|
2007
|
|
3-4 |
p. 182-
1 p.
|
artikel
|
| 34 |
Fetal hypoxia and programming of matrix metalloproteinases
|
Tong, Wenni
|
|
2012
|
|
3-4 |
p. 124-134
11 p.
|
artikel
|
| 35 |
Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi]
|
Kozikowski, Alan P.
|
|
2008
|
|
3-4 |
p. 97-98
2 p.
|
artikel
|
| 36 |
Fragments, network biology and designing multiple ligands
|
Morphy, Richard
|
|
2007
|
|
3-4 |
p. 156-160
5 p.
|
artikel
|
| 37 |
From biomarker strategies to biomarker activities and back
|
van Gool, Alain J.
|
|
2010
|
|
3-4 |
p. 121-126
6 p.
|
artikel
|
| 38 |
Global clinical data interchange standards are here!
|
Souza, Tammy
|
|
2007
|
|
3-4 |
p. 174-181
8 p.
|
artikel
|
| 39 |
Imaging in the cardiovascular and metabolic disease area
|
Comley, Robert A.
|
|
2013
|
|
3-4 |
p. 185-192
8 p.
|
artikel
|
| 40 |
Iminosugars past, present and future: medicines for tomorrow
|
Horne, Graeme
|
|
2011
|
|
3-4 |
p. 107-118
12 p.
|
artikel
|
| 41 |
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
|
Wunberg, Tobias
|
|
2006
|
|
3-4 |
p. 175-180
6 p.
|
artikel
|
| 42 |
Informatic innovations in glycobiology: relevance to drug discovery
|
Mamitsuka, Hiroshi
|
|
2008
|
|
3-4 |
p. 118-123
6 p.
|
artikel
|
| 43 |
In silico drug repositioning – what we need to know
|
Liu, Zhichao
|
|
2013
|
|
3-4 |
p. 110-115
6 p.
|
artikel
|
| 44 |
In silico selection of active siRNA
|
Patzel, Volker
|
|
2007
|
|
3-4 |
p. 139-148
10 p.
|
artikel
|
| 45 |
In vitro models for human skin disease
|
Semlin, Lydia
|
|
2011
|
|
3-4 |
p. 132-139
8 p.
|
artikel
|
| 46 |
Isotopic biomarker discovery and application in translational medicine
|
Bayele, Henry K.
|
|
2010
|
|
3-4 |
p. 127-136
10 p.
|
artikel
|
| 47 |
Keynote review: Chromatin control and cancer-drug discovery: realizing the promise
|
Inche, Adam G.
|
|
2006
|
|
3-4 |
p. 97-109
13 p.
|
artikel
|
| 48 |
Lead optimization in the nondrug-like space
|
Zhao, Hongyu
|
|
2011
|
|
3-4 |
p. 158-163
6 p.
|
artikel
|
| 49 |
Liposomal drug formulations in cancer therapy: 15 years along the road
|
Slingerland, Marije
|
|
2012
|
|
3-4 |
p. 160-166
7 p.
|
artikel
|
| 50 |
Liquid chromatography–mass spectrometry in in vitro drug metabolite screening
|
Tolonen, Ari
|
|
2009
|
|
3-4 |
p. 120-133
14 p.
|
artikel
|
| 51 |
Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer
|
Loven, David
|
|
2013
|
|
3-4 |
p. 193-201
9 p.
|
artikel
|
| 52 |
Manipulating molecular architecture in parallel
|
Edwards, Paul
|
|
2007
|
|
3-4 |
p. 183-184
2 p.
|
artikel
|
| 53 |
Mechanistic systems modeling to guide drug discovery and development
|
Schmidt, Brian J.
|
|
2013
|
|
3-4 |
p. 116-127
12 p.
|
artikel
|
| 54 |
Medicines for tropical diseases; support through tax-incentives
|
John, Jacob E.
|
|
2011
|
|
3-4 |
p. 91-92
2 p.
|
artikel
|
| 55 |
Mesopore-assisted profiling strategies in clinical proteomics for drug/target discovery
|
Savino, Rocco
|
|
2012
|
|
3-4 |
p. 143-152
10 p.
|
artikel
|
| 56 |
Micro- and nanofluidic systems for high-throughput biological screening
|
Hong, Jongin
|
|
2009
|
|
3-4 |
p. 134-146
13 p.
|
artikel
|
| 57 |
Modelling iterative compound optimisation using a self-avoiding walk
|
Delaney, John
|
|
2009
|
|
3-4 |
p. 198-207
10 p.
|
artikel
|
| 58 |
Monitor – An antitumor dual inhibitor of cyclin-dependent kinases and Aurora kinases
|
Westwell, Andrew D.
|
|
2006
|
|
3-4 |
p. 182-
1 p.
|
artikel
|
| 59 |
Monitor – A proapoptotic resveratrol analogue
|
Westwell, Andrew D.
|
|
2006
|
|
3-4 |
p. 182-183
2 p.
|
artikel
|
| 60 |
Monitor – Combinatorial approach towards the discovery of tryptase inhibitors
|
Edwards, Paul
|
|
2006
|
|
3-4 |
p. 181-182
2 p.
|
artikel
|
| 61 |
Monitor – Molecules
|
Edwards, Paul
|
|
2006
|
|
3-4 |
p. 181-
1 p.
|
artikel
|
| 62 |
MRI as a tool for evaluation of oral controlled release dosage forms
|
Dorożyński, Przemysław P.
|
|
2012
|
|
3-4 |
p. 110-123
14 p.
|
artikel
|
| 63 |
Nanotechnology in ocular drug delivery
|
Sahoo, Sanjeeb K.
|
|
2008
|
|
3-4 |
p. 144-151
8 p.
|
artikel
|
| 64 |
Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy
|
Zhang, Erlong
|
|
2011
|
|
3-4 |
p. 140-146
7 p.
|
artikel
|
| 65 |
Oncology exploration: charting cancer medicinal chemistry space
|
Lloyd, David G.
|
|
2006
|
|
3-4 |
p. 149-159
11 p.
|
artikel
|
| 66 |
Ophthalmic light sensitive nanocarrier systems
|
Christie, Jennifer G.
|
|
2008
|
|
3-4 |
p. 124-134
11 p.
|
artikel
|
| 67 |
Optimizing the use of open-source software applications in drug discovery
|
Geldenhuys, Werner J.
|
|
2006
|
|
3-4 |
p. 127-132
6 p.
|
artikel
|
| 68 |
Orphan drugs: the regulatory environment
|
Franco, Pedro
|
|
2013
|
|
3-4 |
p. 163-172
10 p.
|
artikel
|
| 69 |
Outsourcing lead optimization: the eye of the storm
|
Clark, David E.
|
|
2011
|
|
3-4 |
p. 147-157
11 p.
|
artikel
|
| 70 |
Peptides in DNA delivery: current insights and future directions
|
Mann, Anita
|
|
2008
|
|
3-4 |
p. 152-160
9 p.
|
artikel
|
| 71 |
Perispinal etanercept for neuroinflammatory disorders
|
Tobinick, Edward
|
|
2009
|
|
3-4 |
p. 168-177
10 p.
|
artikel
|
| 72 |
PET and SPECT tracers for glutamate receptors
|
Majo, Vattoly J.
|
|
2013
|
|
3-4 |
p. 173-184
12 p.
|
artikel
|
| 73 |
Phenothiazine: the seven lives of pharmacology's first lead structure
|
Ohlow, Maike J.
|
|
2011
|
|
3-4 |
p. 119-131
13 p.
|
artikel
|
| 74 |
Plant-derived compounds in clinical trials
|
Saklani, Arvind
|
|
2008
|
|
3-4 |
p. 161-171
11 p.
|
artikel
|
| 75 |
Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease
|
Kooloos, Wouter M.
|
|
2007
|
|
3-4 |
p. 125-131
7 p.
|
artikel
|
| 76 |
Practical purification of hydrophilic fragments and lead/drug-like molecules by reverse phase flash chromatography: tips, tricks and contemporary developments
|
Hobbs, Andrew N.
|
|
2013
|
|
3-4 |
p. 148-154
7 p.
|
artikel
|
| 77 |
Predicting druggable binding sites at the protein–protein interface
|
Fuller, Jonathan C.
|
|
2009
|
|
3-4 |
p. 155-161
7 p.
|
artikel
|
| 78 |
Progress towards personalized medicine
|
Bates, Stewart
|
|
2010
|
|
3-4 |
p. 115-120
6 p.
|
artikel
|
| 79 |
Project management of life-science research projects: project characteristics, challenges and training needs
|
Beukers, Margot W.
|
|
2011
|
|
3-4 |
p. 93-98
6 p.
|
artikel
|
| 80 |
Rare disease patient groups as clinical researchers
|
Polich, Ginger R.
|
|
2012
|
|
3-4 |
p. 167-172
6 p.
|
artikel
|
| 81 |
Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease
|
Neres, João
|
|
2008
|
|
3-4 |
p. 110-117
8 p.
|
artikel
|
| 82 |
Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies
|
van der Meel, Roy
|
|
2010
|
|
3-4 |
p. 102-114
13 p.
|
artikel
|
| 83 |
Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups
|
Cavalla, David
|
|
2012
|
|
3-4 |
p. 104-109
6 p.
|
artikel
|
| 84 |
Role of pharmacologically active metabolites in drug discovery and development
|
Fura, Aberra
|
|
2006
|
|
3-4 |
p. 133-142
10 p.
|
artikel
|
| 85 |
SAGE and related approaches for cancer target identification
|
Porter, Dale
|
|
2006
|
|
3-4 |
p. 110-118
9 p.
|
artikel
|
| 86 |
Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective
|
Zhao, Hongyu
|
|
2007
|
|
3-4 |
p. 149-155
7 p.
|
artikel
|
| 87 |
Seeing small molecules in action with bioorthogonal chemistry
|
Raghavan, Anuradha S.
|
|
2009
|
|
3-4 |
p. 178-184
7 p.
|
artikel
|
| 88 |
Selective optimization of side activities: the SOSA approach
|
Wermuth, Camille G.
|
|
2006
|
|
3-4 |
p. 160-164
5 p.
|
artikel
|
| 89 |
Something's got to give: psychiatric disease on the rise and novel drug development on the decline
|
Chandler, Daniel J.
|
|
2013
|
|
3-4 |
p. 202-206
5 p.
|
artikel
|
| 90 |
Strategies and tactics for optimizing the Hit-to-Lead process and beyond—A computational chemistry perspective
|
Manly, Charles J.
|
|
2008
|
|
3-4 |
p. 99-109
11 p.
|
artikel
|
| 91 |
Supporting and developing bioscience in Wales. Showcasing Welsh talent at BioWales 2009
|
Thomas, Sharon
|
|
2009
|
|
3-4 |
p. 113-114
2 p.
|
artikel
|
| 92 |
Target discovery from data mining approaches
|
Yang, Yongliang
|
|
2009
|
|
3-4 |
p. 147-154
8 p.
|
artikel
|
| 93 |
Targeted therapy for neuro-oncology: reviewing the menu
|
Lampson, Lois A.
|
|
2009
|
|
3-4 |
p. 185-191
7 p.
|
artikel
|
| 94 |
Targeting mammalian target of rapamycin (mTOR) for health and diseases
|
Tsang, Chi Kwan
|
|
2007
|
|
3-4 |
p. 112-124
13 p.
|
artikel
|
| 95 |
Targeting structural flexibility in HIV-1 protease inhibitor binding
|
Hornak, Viktor
|
|
2007
|
|
3-4 |
p. 132-138
7 p.
|
artikel
|
| 96 |
Targeting tight junction proteins-significance for drug development
|
Kondoh, Masuo
|
|
2008
|
|
3-4 |
p. 180-186
7 p.
|
artikel
|
| 97 |
Targeting virulence: A new paradigm for antifungals
|
Gauwerky, Katharina
|
|
2009
|
|
3-4 |
p. 214-222
9 p.
|
artikel
|
| 98 |
The application of FAST-NMR for the identification of novel drug discovery targets
|
Powers, Robert
|
|
2008
|
|
3-4 |
p. 172-179
8 p.
|
artikel
|
| 99 |
The formulation of polyhedral boranes for the boron neutron capture therapy of cancer
|
Calabrese, Gianpiero
|
|
2012
|
|
3-4 |
p. 153-159
7 p.
|
artikel
|
| 100 |
The future of drug safety testing: expanding the view and narrowing the focus
|
Stevens, James L.
|
|
2009
|
|
3-4 |
p. 162-167
6 p.
|
artikel
|
| 101 |
The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types
|
Ritchie, Timothy J.
|
|
2011
|
|
3-4 |
p. 164-171
8 p.
|
artikel
|
| 102 |
The impact of microwave-assisted organic synthesis in drug discovery
|
Mavandadi, Farah
|
|
2006
|
|
3-4 |
p. 165-174
10 p.
|
artikel
|
| 103 |
The importance of aryl C–Cl⋯π interaction in ligand–protein binding
|
Yeung, Kap-Sun
|
|
2010
|
|
3-4 |
p. 158-
1 p.
|
artikel
|
| 104 |
The quest for biomarkers in tuberculosis
|
Parida, Shreemanta K.
|
|
2010
|
|
3-4 |
p. 148-157
10 p.
|
artikel
|
| 105 |
Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity
|
Argilés, Josep M.
|
|
2009
|
|
3-4 |
p. 208-213
6 p.
|
artikel
|
| 106 |
The rise of micropharma
|
Barden, Christopher J.
|
|
2010
|
|
3-4 |
p. 84-87
4 p.
|
artikel
|
| 107 |
The routes to orphan drug designation – our recent experience at the FDA
|
Lev, Daniel
|
|
2012
|
|
3-4 |
p. 97-99
3 p.
|
artikel
|
| 108 |
The use of technologies for the discovery of novel chemotherapeutic agents
|
Edwards, Paul
|
|
2009
|
|
3-4 |
p. 223-225
3 p.
|
artikel
|
| 109 |
The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries
|
Modi, Sandeep
|
|
2012
|
|
3-4 |
p. 135-142
8 p.
|
artikel
|
| 110 |
Treating desires not diseases: a pill for every ill and an ill for every pill?
|
Triggle, David. J.
|
|
2007
|
|
3-4 |
p. 161-166
6 p.
|
artikel
|
| 111 |
Uppsala: turning knowledge into profits
|
Neil, Madeleine
|
|
2006
|
|
3-4 |
p. 94-96
3 p.
|
artikel
|
| 112 |
Use of biomarkers in the discovery of novel anti-schizophrenia drugs
|
Mikkelsen, Jens D.
|
|
2010
|
|
3-4 |
p. 137-141
5 p.
|
artikel
|
| 113 |
Where is the hope for drug discovery? Let history tell the future
|
Kong, De-Xin
|
|
2009
|
|
3-4 |
p. 115-119
5 p.
|
artikel
|
| 114 |
Where is the optimism? Warrior teachings to regain the drug discovery spirit
|
Uitdehaag, Joost C.M.
|
|
2007
|
|
3-4 |
p. 105-107
3 p.
|
artikel
|
Tijdschrift beschrijving